Live Breaking News & Updates on Biopharmaceutical services
Stay updated with breaking news from Biopharmaceutical services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biodesix, Inc. (NASDAQ:BDSX) Q1 2024 Earnings Call Transcript insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.
Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Persistent, high double-digit growth in Lung Diagnostic test volume - growing 65% in FY2023 versus FY2022 - and the sixth consecutive quarter with greater than 50% year-over-year growth;
Biodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call Transcript August 7, 2023 Biodesix, Inc. misses on earnings expectations. Reported EPS is $-0.17013 EPS, expectations were $0.21. Operator: Good day and thank you for standing by. Welcome to the Biodesix Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After […]
Operator: Good day, and thank you for standing by. Welcome to the Biodesix Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time all participants are in a listen-only mode.
Toronto, ON (PRWEB) March 02, 2023 -- Biological medicines have had a tremendous impact on the treatment of medical conditions, such as diabetes, Crohn’s
Search jobs KCAS Bioanalytical and Biomarker Services Welcomes Dr. Greg Veltri as Scientific Director of Biopharmaceutical Services KANSAS CITY, Kan.--(BUSINESS WIRE)--KCAS Bioanalytical and Biomarker Services (KCAS), a laboratory services focused contract research organization (CRO) is pleased to announce the expansion of their Biopharmaceutical Services team. Dr. Greg Veltri joins KCAS as a Scientific Director of Cell Based Development Technologies. Dr. Veltri’s role at KCAS will be to provide vision, leadership, and scientific expertise to expand the flow cytometry capabilities to support BioPharma clients’ Cell and Gene Therapy development programs. He has dedicated over 20 years of his scientific career to the advancement of the field of flow cytometry within top tier academic, healthcare and commercial organizations. Throughout his career, Dr. Veltri has successfully mentored and trained many exceptional scientists as well as advanced the field of flow cytometry through the development of innovative flow cytometry acquisition and analysis software as well high-parameter spectral analyzer/flow cytometry instrumentation.